FR14C0041I2 - Derive polycyclique de la carbamoylpyridone a activite inhibitrice sur l'integrase du vih - Google Patents

Derive polycyclique de la carbamoylpyridone a activite inhibitrice sur l'integrase du vih

Info

Publication number: FR14C0041I2
Authority: FR; France
Prior art keywords: carbamoylpyridone; inhibitory activity; hiv integrase; polycyclic derivative; polycyclic
Prior art date: 2005-04-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR14C0041C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Shionogi and Co Ltd

ViiV Healthcare Co

Original Assignee

Shionogi and Co Ltd

ViiV Healthcare Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-28

Filing date

2014-05-19

Publication date

2015-11-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37215098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0041(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-05-19 Application filed by Shionogi and Co Ltd, ViiV Healthcare Co filed Critical Shionogi and Co Ltd

2014-06-27 Publication of FR14C0041I1 publication Critical patent/FR14C0041I1/fr

2015-11-13 Application granted granted Critical

2015-11-13 Publication of FR14C0041I2 publication Critical patent/FR14C0041I2/fr

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physiology (AREA)
Nutrition Science (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

FR14C0041C 2005-04-28 2014-05-19 Derive polycyclique de la carbamoylpyridone a activite inhibitrice sur l'integrase du vih Active FR14C0041I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2005131161		2005-04-28
JP2005312076		2005-10-27
PCT/US2006/016604 WO2006116764A1 (fr)	2005-04-28	2006-04-28	Derive polycyclique de la carbamoylpyridone a activite inhibitrice sur l'integrase du vih

Publications (2)

Publication Number	Publication Date
FR14C0041I1 FR14C0041I1 (fr)	2014-06-27
FR14C0041I2 true FR14C0041I2 (fr)	2015-11-13

Family

ID=37215098

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR14C0041C Active FR14C0041I2 (fr)	2005-04-28	2014-05-19	Derive polycyclique de la carbamoylpyridone a activite inhibitrice sur l'integrase du vih

Country Status (29)

Country	Link
US (22)	US8129385B2 (fr)
EP (9)	EP3284519A1 (fr)
JP (2)	JP4295353B2 (fr)
KR (4)	KR101580310B1 (fr)
AU (1)	AU2006239177B8 (fr)
BR (1)	BRPI0610030B8 (fr)
CA (1)	CA2606282C (fr)
CY (7)	CY1115151T1 (fr)
DK (6)	DK3372281T3 (fr)
EA (1)	EA014162B1 (fr)
ES (7)	ES2446324T3 (fr)
FI (1)	FIC20210017I1 (fr)
FR (1)	FR14C0041I2 (fr)
HK (4)	HK1107227A1 (fr)
HU (6)	HUE044978T2 (fr)
IL (4)	IL186555A (fr)
LT (4)	LT3045206T (fr)
LU (2)	LU92446I2 (fr)
MA (1)	MA29460B1 (fr)
MX (2)	MX302718B (fr)
NL (2)	NL300676I2 (fr)
NO (5)	NO339525B1 (fr)
NZ (1)	NZ562339A (fr)
PL (5)	PL3372281T3 (fr)
PT (5)	PT3284520T (fr)
SI (6)	SI3045206T1 (fr)
TW (1)	TWI378931B (fr)
VN (1)	VN34404A1 (fr)
WO (1)	WO2006116764A1 (fr)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2360222T3 (es)	2003-12-24	2011-06-02	Biota Scientific Management Pty. Ltd.	Agentes policíclicos para el tratamiento de infecciones respiratorias por virus sincicial.
US7273859B2 (en) *	2004-05-12	2007-09-25	Bristol-Myers Squibb Company	HIV integrase inhibitors: cyclic pyrimidinone compounds
SI3045206T1 (en)	2005-04-28	2018-07-31	Viiv Healthcare Company	A polycyclic carbamoylpyridone derivative with inhibitory activity for the HIV integrase
US7741315B2 (en)	2005-05-10	2010-06-22	Merck Sharp & Dohme Corp.	HIV integrase inhibitors
ATE517899T1 (de)	2005-10-04	2011-08-15	Angeletti P Ist Richerche Bio	Hiv-integrasehemmer
JP5131689B2 (ja) *	2005-10-27	2013-01-30	塩野義製薬株式会社	Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
TWI423972B (zh)	2006-09-28	2014-01-21	Biota Scient Management	治療呼吸系融合細胞病毒感染之多環劑
JP5269086B2 (ja)	2007-11-15	2013-08-21	ギリアードサイエンシスインコーポレーテッド	ヒト免疫不全ウイルスの複製阻害薬
WO2009062288A1 (fr)	2007-11-15	2009-05-22	Boehringer Ingelheim International Gmbh	Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EA201200631A1 (ru)	2007-11-16	2012-11-30	Джилид Сайенсиз, Инк.	Ингибиторы репликации вируса иммунодефицита человека
PT2320908E (pt)	2008-07-25	2014-03-06	Shionogi & Co	Pró-fármacos de dolutegravir
ES2395705T3 (es) *	2008-07-25	2013-02-14	Glaxosmithkline Llc	Compuestos químicos
WO2010011815A1 (fr) *	2008-07-25	2010-01-28	Smithkline Beecham Corporation	Composés chimiques
WO2010011818A1 (fr) *	2008-07-25	2010-01-28	Smithkline Beecham Corporation	Composés chimiques
KR101700267B1 (ko) *	2008-07-25	2017-01-26	비이브 헬쓰케어 컴퍼니	화합물
AU2014277831C1 (en) *	2008-12-11	2022-10-06	Shionogi & Co. Ltd.	Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
JP5572168B2 (ja) *	2008-12-11	2014-08-13	ビーブ・ヘルスケア・カンパニー	カルバモイルピリドンｈｉｖインテグラーゼ阻害剤の製造方法および中間体
KR101663222B1 (ko) *	2008-12-11	2016-10-06	시오노기세야쿠 가부시키가이샤	말톨 에테르 방법 및 중간체
BRPI0923217A2 (pt)	2008-12-11	2017-05-23	Glaxosmithkline Llc	processos para a preparação de um composto de piridona, e para a preparação de uma forma cristalina, composto, sal ou um hidrato deste, forma cristalina de um sal de sódio ou um hidrato deste, e, composição farmacêutica.
TWI518084B (zh)	2009-03-26	2016-01-21	鹽野義製藥股份有限公司	哌喃酮與吡啶酮衍生物之製造方法
ES2671550T3 (es)	2009-06-15	2018-06-07	Shionogi & Co., Ltd.	Derivado de carbamoilpiridona policíclica sustituida
WO2011011483A1 (fr) *	2009-07-22	2011-01-27	Glaxosmithkline Llc	Composés chimiques
CA2777664C (fr)	2009-10-13	2014-06-10	Johannes Wilhelmus J. Thuring	Inhibiteurs macrocycliques d'integrase
AU2014202406C1 (en) *	2010-01-27	2019-03-07	Viiv Healthcare Company	Antiviral therapy
AU2014202404C1 (en) *	2010-01-27	2022-06-23	Viiv Healthcare Company	Antiviral therapy
MA34002B1 (fr) *	2010-01-27	2013-02-01	Glaxosmithkline Llc	Thérapie antivirale
TWI508968B (zh)	2010-02-08	2015-11-21	Biota Scient Management	用於治療呼吸道融合性病毒感染的化合物
SG183484A1 (en) *	2010-02-26	2012-09-27	Japan Tobacco Inc	1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
TWI582097B (zh)	2010-03-23	2017-05-11	Ｖｉｉｖ醫療保健公司	製備胺甲醯吡啶酮衍生物及中間體之方法
RU2567385C2 (ru)	2010-04-02	2015-11-10	ЯНССЕН Ар ЭНД Ди АЙРЛЭНД	Макроциклические ингибиторы интегразы
US9216995B2 (en)	2010-04-12	2015-12-22	Shionogi & Co., Ltd.	Pyridone derivative having integrase inhibitory activity
WO2012006104A2 (fr)	2010-06-28	2012-01-12	Academia Sinica, Taiwan	Composés et procédés destinés au traitement d'une infection par la tuberculose
PT3456721T (pt) *	2010-08-05	2021-05-04	Shionogi & Co	Método de produção de compostos possuindo atividade inibitória de integrase de vih
TWI577377B (zh) *	2010-09-16	2017-04-11	Ｖｉｉｖ醫療保健公司	醫藥組合物
WO2012039414A1 (fr)	2010-09-24	2012-03-29	塩野義製薬株式会社	Promédicament dérivé de carbamoylpyridone polycyclique substituée
US8796303B2 (en)	2010-11-26	2014-08-05	Biota Scientific Management Pty Ltd.	Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections
US20140213553A1 (en) *	2011-05-03	2014-07-31	Concert Pharmaceuticals Inc.	Carbamoylpyridone derivatives
ES2613180T3 (es)	2011-09-14	2017-05-23	Mapi Pharma Limited	Forma amorfa de la sal sódica dolutegravir
BR112014008896A2 (pt) *	2011-10-12	2017-04-18	Shionogi & Co	derivado de piridona policíclico tendo atividade inibidora de integrase
PE20142454A1 (es)	2011-12-28	2015-02-07	Global Blood Therapeutics Inc	Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
US9012450B2 (en)	2011-12-28	2015-04-21	Global Blood Therapeutics, Inc.	Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US9714243B2 (en)	2012-12-17	2017-07-25	Merck Sharp & Dohme Corp.	4-pyridinonetriazine derivatives as HIV integrase inhibitors
PT3608325T (pt) *	2012-12-21	2022-10-17	Gilead Sciences Inc	Compostos carbamoílpiridona policíclicos e sua utilização farmacêutica
SG11201504982PA (en) *	2012-12-27	2015-07-30	Japan Tobacco Inc	SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR
CA2897137A1 (fr)	2013-02-18	2014-08-21	Ratiopharm Gmbh	Forme galenique pharmaceutique solide de dolutegravir
EP2767272A1 (fr)	2013-02-18	2014-08-20	Ratiopharm GmbH	Forme posologique pharmaceutique solide de dolutegravir
WO2014128545A2 (fr)	2013-02-19	2014-08-28	Aurobindo Pharma Limited	Procédé amélioré pour la préparation du dolutégravir
MY183637A (en)	2013-03-15	2021-03-04	Global Blood Therapeutics Inc	Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en)	2013-03-15	2016-10-04	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (fr)	2013-03-15	2014-09-18	Global Blood Therapeutics, Inc.	Composés aldéhydes substitués et leurs procédés d'utilisation pour accroître l'oxygénation tissulaire
EA034922B1 (ru)	2013-03-15	2020-04-07	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
US20140274961A1 (en)	2013-03-15	2014-09-18	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en)	2013-03-15	2015-02-10	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en)	2013-03-15	2017-03-28	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
SG11201507453VA (en)	2013-03-15	2015-10-29	Global Blood Therapeutics Inc	Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en)	2013-03-15	2017-10-31	Global Blood Therapeutics, Inc.	Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en)	2013-03-15	2016-08-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en)	2013-03-15	2019-04-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
WO2014172188A2 (fr)	2013-04-16	2014-10-23	Merck Sharp & Dohme Corp.	Composés dérivés de 4-pyridone et leurs utilisations en tant qu'inhibiteurs de la vih intégrase
EP3008044B1 (fr) *	2013-06-13	2018-11-21	Merck Sharp & Dohme Corp.	Composés hétérocycliques tricycliques fusionnés utiles en tant qu'inhibiteurs de l'intégrase du vih
WO2015001572A2 (fr) *	2013-07-04	2015-01-08	Hetero Research Foundation	Procédé pour la préparation d'intermédiaire de dolutégravir
PT3019503T (pt)	2013-07-12	2017-11-27	Gilead Sciences Inc	Compostos carbamoílpiridona- policíclicos e seu uso para o tratamento de infecções por hiv
NO2865735T3 (fr)	2013-07-12	2018-07-21
WO2015009927A1 (fr)	2013-07-17	2015-01-22	Ratiopharm Gmbh	Sels de dolutégravir
WO2015019310A1 (fr)	2013-08-07	2015-02-12	Mylan Laboratories Ltd	Procédé de préparation de dolutégravir et ses intermédiaires
WO2015039348A1 (fr) *	2013-09-23	2015-03-26	Merck Sharp & Dohme Corp.	Composés hétérocycliques tétracycliques utiles comme inhibiteurs de l'intégrase du vih
TN2016000090A1 (en)	2013-09-27	2017-07-05	Merck Sharp & Dohme	Substituted quinolizine derivatives useful as hiv integrase inhibitors.
EA201992707A1 (ru)	2013-11-18	2020-06-30	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
WO2015092752A1 (fr)	2013-12-20	2015-06-25	Mylan Laboratories Ltd.	Nouvelle forme cristalline de dolutegravir sodium
WO2015089847A1 (fr)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Composés à hétérocycles spirocycliques utiles en tant qu'inhibiteurs d'intégrase du vih
US9808428B2 (en)	2014-01-14	2017-11-07	Board Of Regents Of The University Of Nebraska	Compositions and methods for the delivery of therapeutics
EP3096763B1 (fr) *	2014-01-21	2019-12-25	Laurus Labs Limited	Nouveau procédé de préparation de dolutégravir et de ses sels pharmaceutiquement acceptables
CN114181195A (zh)	2014-02-07	2022-03-15	全球血液疗法股份有限公司	一种化合物的结晶多晶型物
WO2015138933A1 (fr)	2014-03-13	2015-09-17	Assia Chemical Industries Ltd.	Formes à l'état solide de dolutegravir sodium
CN106866702B (zh) *	2014-03-19	2019-03-19	杭州普晒医药科技有限公司	德罗格韦钠盐的晶型及其制备方法
WO2015140569A1 (fr)	2014-03-20	2015-09-24	Cipla Limited	Composition pharmaceutique
ZA201503540B (en) *	2014-05-20	2016-10-26	Cipla Ltd	Process for preparing polycyclic carbamoyl pyridone derivatives
TW201613936A (en) *	2014-06-20	2016-04-16	Gilead Sciences Inc	Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (zh) *	2014-06-20	2019-11-21	美商基利科學股份有限公司	多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (fr) *	2014-06-20	2018-06-23
JPWO2016027879A1 (ja) *	2014-08-22	2017-06-01	塩野義製薬株式会社	インテグラーゼ阻害活性を有する多環性ピリドン誘導体
EP3203995A4 (fr)	2014-10-09	2019-05-15	Board of Regents of the University of Nebraska	Compositions et méthodes d'administration d'agents thérapeutiques
WO2016092527A1 (fr) *	2014-12-12	2016-06-16	Sun Pharmaceutical Industries Limited	Procédé de préparation de dolutégravir
TWI695003B (zh)	2014-12-23	2020-06-01	美商基利科學股份有限公司	多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3045461A1 (fr)	2015-01-16	2016-07-20	LEK Pharmaceuticals d.d.	Procédés de préparation de Dolutégravir et de ses analogues
CN107531614B (zh)	2015-02-06	2020-04-10	迈兰实验室有限公司	德罗格韦的制备方法
CZ201599A3 (cs)	2015-02-13	2016-08-24	Zentiva, K.S.	Pevné formy solí dolutegraviru a způsob jejich přípravy
WO2016154527A1 (fr) *	2015-03-26	2016-09-29	Merck Sharp & Dohme Corp.	Dérivés de quinolizine substitués par un phosphate utiles en tant qu'inhibiteurs de l'intégrase du vih
MA41841A (fr)	2015-03-30	2018-02-06	Global Blood Therapeutics Inc	Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
PT3466490T (pt)	2015-04-02	2020-12-24	Gilead Sciences Inc	Compostos de carbamoilpiridona policíclicos e sua utilização farmacêutica
NZ736259A (en) *	2015-04-28	2019-09-27	Shionogi & Co	Substituted polycyclic pyridone derivative and prodrugs thereof
WO2016187788A1 (fr)	2015-05-25	2016-12-01	Merck Sharp & Dohme Corp.	Composés hétérocycliques tricycliques fusionnés utiles pour traiter l'infection au vih
CZ2015537A3 (cs)	2015-08-04	2017-02-15	Zentiva, K.S.	Pevné formy amorfního dolutegraviru
US10597404B2 (en)	2015-08-19	2020-03-24	Laurus Labs Ltd.	Polymorphs of dolutegravir and salts thereof
CN108348473B (zh)	2015-11-09	2021-06-18	吉利德科学公司	治疗人免疫缺陷病毒的治疗组合物
EP3377066B1 (fr)	2015-11-17	2021-04-07	Merck Sharp & Dohme Corp.	Dérivés de pyridotriazine amido-substitués utiles en tant qu'inhibiteurs de l'intégrase du vih
TW201731509A (zh)	2015-12-04	2017-09-16	全球血液治療公司	針對２-羥基-６-（（２-（１-異丙基-１ｈ-吡唑-５-基）吡啶-３-基）甲氧基）-苯甲醛之劑量方案
WO2017106071A1 (fr)	2015-12-15	2017-06-22	Merck Sharp & Dohme Corp.	Dérivés de quinolizine spirocycliques utiles en tant qu'inhibiteurs de l'intégrase du vih
WO2017109649A1 (fr)	2015-12-21	2017-06-29	Lupin Limited	Procédé de préparation d'inhibiteurs de l'intégrase du vih
TWI663160B (zh)	2016-05-12	2019-06-21	全球血液治療公司	用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
WO2017208105A1 (fr)	2016-05-30	2017-12-07	Lupin Limited	Nouvelle forme cristalline de dolutégravir sodique
US11117904B2 (en)	2016-06-23	2021-09-14	Viiv Healthcare Company	Compositions and methods for the delivery of therapeutics
EP3496718A4 (fr)	2016-08-08	2020-01-22	Hetero Labs Limited	Compositions antirétrovirales
WO2018029565A1 (fr)	2016-08-08	2018-02-15	Hetero Labs Limited	Composition antirétrovirale multi-classe
CN109789144B (zh) *	2016-08-12	2022-04-15	马德拉医疗公司	蛋白激酶调节剂
WO2018042332A1 (fr)	2016-08-31	2018-03-08	Glaxosmithkline Intellectual Property (No.2) Limited	Combinaisons, utilisations et traitements correspondants
EP3515438B1 (fr) *	2016-09-21	2022-03-02	Merck Sharp & Dohme Corp.	Système d'administration de médicaments pour l'administration d'inhibiteurs de l'intégrase
TW202332423A (zh)	2016-10-12	2023-08-16	美商全球血液治療公司	包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JOP20190130A1 (ar)	2016-12-02	2019-06-02	Merck Sharp & Dohme	مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
AU2017367714B2 (en)	2016-12-02	2020-11-12	Merck Sharp & Dohme Corp.	Tricyclic heterocycle compounds useful as HIV integrase inhibitors
WO2018109786A1 (fr)	2016-12-16	2018-06-21	Cipla Limited	Nouveaux polymorphes et sels de dérivés de carbamoyle pyridone polycycliques
EP3573984A4 (fr)	2017-01-26	2020-07-29	Merck Sharp & Dohme Corp.	Dérivés de quinolizine substitués utiles en tant qu'inhibiteurs de l'intégrase du vih
EP3363802B1 (fr)	2017-02-16	2019-11-20	Sandoz AG	Forme cristalline du sel de sodium de cabotegravir
AU2018221379B2 (en)	2017-02-16	2021-11-04	ViiV Healthcare UK (No.3) Limited	Crystalline forms of cabotegravir sodium
US20200138845A1 (en) *	2017-07-18	2020-05-07	Viiv Healthcare Company	Combination Drug Therapy
KR20200031658A (ko)	2017-07-21	2020-03-24	비이브 헬쓰케어 컴퍼니	Hib 감염 및 aids를 치료하기 위한 요법
WO2019048808A1 (fr)	2017-09-07	2019-03-14	Cipla Limited	Nouveaux polymorphes du dolutégravir sodique
US11286262B2 (en)	2017-10-06	2022-03-29	Shionogi & Co., Ltd.	Stereoselective process for preparing substituted polycyclic pyridone derivatives
CA3126348A1 (fr)	2018-01-12	2020-07-18	Board Of Regents Of The University Of Nebraska	Promedicaments antiviraux et formulations de ceux-ci
WO2019159199A1 (fr)	2018-02-16	2019-08-22	Cipla Limited	Procédé à flux continu pour la préparation de dérivés de carbamoylpyridone polycycliques à ingrédients pharmaceutiquement actifs et intermédiaires de ceux-ci
CA3132832A1 (fr)	2018-04-09	2019-10-17	Howard E. Gendelman	Promedicaments antiviraux et formulations de ceux-ci
CN110526930B (zh)	2018-05-23	2022-06-03	莫云芬	抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
CN112513042B (zh)	2018-05-31	2023-09-29	盐野义制药株式会社	多环氨基甲酰基吡啶酮衍生物
SG11202011386QA (en)	2018-05-31	2020-12-30	Shionogi & Co	Polycyclic pyridone derivative
TWI820141B (zh) *	2018-05-31	2023-11-01	日商鹽野義製藥股份有限公司	衍生物
WO2020012408A2 (fr)	2018-07-12	2020-01-16	Laurus Labs Limited	Procédé de purification de dérivés de carbamoylpyridone polycycliques protégés
US11014884B2 (en)	2018-10-01	2021-05-25	Global Blood Therapeutics, Inc.	Modulators of hemoglobin
EP4234561A3 (fr)	2018-10-22	2023-09-13	Board of Regents of the University of Nebraska	Promédicaments antiviraux et nanoformulations de ceux-ci
ES2927041T3 (es)	2019-03-22	2022-11-03	Gilead Sciences Inc	Compuestos de carbamoilpiridona tricíclicos con puente y su uso farmacéutico
RU2717101C1 (ru) *	2019-06-03	2020-03-18	Андрей Александрович Иващенко	Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en)	2019-06-20	2020-12-24	Bell Helicopter Textron Inc.	Low-drag rotor blade extension
US11248005B2 (en)	2019-07-08	2022-02-15	Lupin Limited	Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
WO2021107066A1 (fr)	2019-11-28	2021-06-03	塩野義製薬株式会社	Agent pharmaceutique prophylactique et thérapeutique pour maladies infectieuses à vih, caractérisé en ce qu'il comprend une combinaison d'un inhibiteur d'intégrase et d'un agent anti-vih
IL293566A (en)	2019-12-09	2022-08-01	Viiv Healthcare Co	Pharmaceutical preparations containing Cabotgravir
BR112022015771A2 (pt) *	2020-02-24	2022-10-11	Gilead Sciences Inc	Compostos tetracíclicos para tratar a infecção por hiv
US20230218644A1 (en)	2020-04-16	2023-07-13	Som Innovation Biotech, S.A.	Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
JP2023539344A (ja)	2020-09-01	2023-09-13	ヴィーブ、ヘルスケア、カンパニー	カボテグラビルおよびレボノルゲストレルの組合せ
WO2022079739A1 (fr)	2020-10-14	2022-04-21	Cipla Limited	Compositions à dose fixe de cabotégravir et de rilpivirine
JP2024500322A (ja)	2020-12-07	2024-01-09	ヴィーブ、ヘルスケア、カンパニー	併用療法
TWI824384B (zh)	2021-01-19	2023-12-01	美商基利科學股份有限公司	經取代之吡啶并三𠯤化合物及其用途
WO2022253294A1 (fr)	2021-06-03	2022-12-08	江苏恒瑞医药股份有限公司	Composé de pyridone ayant une activité inhibitrice d'intégrase et utilisation pharmaceutique de celui-ci
CN114230579A (zh) *	2021-11-12	2022-03-25	南京艾迪医药科技有限公司	多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
WO2023102374A1 (fr)	2021-12-03	2023-06-08	Viiv Healthcase Company	Procédé de synthèse de (r)-3-aminobutan-1-ol
TWI843506B (zh)	2022-04-06	2024-05-21	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
US20240270756A1 (en) *	2023-01-18	2024-08-15	Ascletis Bioscience Co., Ltd.	Integrase Inhibitor and Use Thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3959316A (en) *	1972-03-13	1976-05-25	Snam Progetti S.P.A.	Procedure for propylene oxide synthesis
JPH0296506A (ja)	1988-09-30	1990-04-09	Daicel Chem Ind Ltd	除草剤組成物
JP2533796B2 (ja) *	1988-10-18	1996-09-11	ダイセル化学工業株式会社	５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2551472B2 (ja)	1988-10-18	1996-11-06	ダイセル化学工業株式会社	５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
US6093732A (en)	1997-12-22	2000-07-25	Pharmacia & Upjohn Company	4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
WO2001095905A1 (fr) †	2000-06-14	2001-12-20	Shionogi & Co., Ltd.	Inhibiteur d'enzymes possedant deux ions metal divalents en tant que centres actifs
US6580562B2 (en)	2000-07-24	2003-06-17	Yazaki Corporation	On-vehicle display unit
US6384263B1 (en)	2000-08-04	2002-05-07	E. I. Du Pont De Nemours And Company	Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane
ATE364385T1 (de)	2000-10-12	2007-07-15	Merck & Co Inc	Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
JP2003032772A (ja)	2001-07-12	2003-01-31	Foster Electric Co Ltd	耳掛け式イヤホン
BR0211750A (pt)	2001-08-10	2004-10-13	Shionogi & Co	Agente antiviral
US7232819B2 (en)	2001-10-26	2007-06-19	Istituto Di Ricerche Di Biologia P. Angeletti S.P.A.	Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
CN102219750B (zh)	2001-10-26	2013-05-29	P.安杰莱蒂分子生物学研究所	关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂
CA2472372C (fr)	2002-01-17	2010-08-17	Melissa Egbertson	Carboxamides hydroxynaphthyridinone utiles comme inhibiteurs de l'integrase du vih
US7109186B2 (en)	2002-07-09	2006-09-19	Bristol-Myers Squibb Company	HIV integrase inhibitors
WO2004024693A1 (fr)	2002-08-13	2004-03-25	Shionogi & Co., Ltd.	Compose heterocyclique a activite inhibitrice de l'integrase du vih
CA2498111A1 (fr)	2002-09-11	2004-03-25	Merck & Co., Inc.	Composes de dihydroxypyridopyrazine-1,6-diones utiles en tant qu'inhibiteurs de l'integrase du vih
NZ540729A (en)	2002-12-27	2008-03-28	Angeletti P Ist Richerche Bio	Tetrahydro-4H-pyrido[1,2-a]pyrimidines and related compounds useful as HIV integrase inhibitors
US6960680B2 (en)	2003-01-08	2005-11-01	Rhodia Chirex, Inc.	Manufacture of water-soluble β-hydroxynitriles
JP2004244320A (ja)	2003-02-10	2004-09-02	Shionogi & Co Ltd	含窒素複素環抗ウイルス剤
WO2004101512A2 (fr)	2003-05-13	2004-11-25	Smithkline Beecham Corporation	Inihbiteurs de l'integrase de la naphtyridine
AU2003273190A1 (en) *	2003-08-12	2005-02-25	Rachel Beijer	Scheduled message service
TW200510425A (en) *	2003-08-13	2005-03-16	Japan Tobacco Inc	Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP4530642B2 (ja)	2003-10-31	2010-08-25	オリンパス株式会社	内視鏡装置
KR20070002006A (ko)	2004-02-11	2007-01-04	스미스클라인 비참 코포레이션	Ｈｉｖ 인테그라제 억제제
AU2005221864A1 (en)	2004-03-09	2005-09-22	Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa	HIV integrase inhibitors
CN1929737A (zh) †	2004-03-09	2007-03-14	默克公司	Hiv整合酶抑制剂
CN1964975B (zh)	2004-05-07	2011-11-30	默沙东公司	Hiv整合酶抑制剂
WO2006066414A1 (fr)	2004-12-23	2006-06-29	Virochem Pharma Inc.	Hydroxydihydropyridopy razine-1,8-diones et procedes d’inhibition de l’integrase du vih
ATE516026T1 (de)	2005-02-21	2011-07-15	Shionogi & Co	Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung
US7981879B2 (en)	2005-03-31	2011-07-19	Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A.	HIV integrase inhibitors
SI3045206T1 (en) *	2005-04-28	2018-07-31	Viiv Healthcare Company	A polycyclic carbamoylpyridone derivative with inhibitory activity for the HIV integrase
JP2005312076A (ja)	2005-05-26	2005-11-04	Olympus Corp	電子撮像装置
EP1910363A4 (fr)	2005-08-04	2010-05-26	Glaxosmithkline Llc	Inhibiteurs de l'integrase du vih
JP5131689B2 (ja)	2005-10-27	2013-01-30	塩野義製薬株式会社	Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体

2006
- 2006-04-28 SI SI200632268T patent/SI3045206T1/en unknown
- 2006-04-28 KR KR1020147017235A patent/KR101580310B1/ko active IP Right Grant
- 2006-04-28 SI SI200631747T patent/SI2465580T1/sl unknown
- 2006-04-28 ES ES12159082.2T patent/ES2446324T3/es active Active
- 2006-04-28 SI SI200632344T patent/SI3284520T1/sl unknown
- 2006-04-28 KR KR1020137028203A patent/KR101504998B1/ko active IP Right Grant
- 2006-04-28 EP EP17195276.5A patent/EP3284519A1/fr not_active Withdrawn
- 2006-04-28 HU HUE17195280 patent/HUE044978T2/hu unknown
- 2006-04-28 EP EP12159082.2A patent/EP2465580B1/fr active Active
- 2006-04-28 LT LTEP16154531.4T patent/LT3045206T/lt unknown
- 2006-04-28 VN VN201300151A patent/VN34404A1/vi unknown
- 2006-04-28 EP EP18166621.5A patent/EP3372281B1/fr active Active
- 2006-04-28 ES ES16154531T patent/ES2667868T5/es active Active
- 2006-04-28 PL PL18166621T patent/PL3372281T3/pl unknown
- 2006-04-28 KR KR1020077027734A patent/KR101363875B1/ko active IP Right Review Request
- 2006-04-28 DK DK18166621.5T patent/DK3372281T3/da active
- 2006-04-28 EP EP06758843.4A patent/EP1874117B8/fr active Active
- 2006-04-28 EP EP17156763.9A patent/EP3187226A1/fr not_active Withdrawn
- 2006-04-28 NZ NZ562339A patent/NZ562339A/en unknown
- 2006-04-28 KR KR1020157036007A patent/KR101848819B1/ko active IP Right Review Request
- 2006-04-28 PT PT17195280T patent/PT3284520T/pt unknown
- 2006-04-28 MX MX2007013351A patent/MX302718B/es active IP Right Grant
- 2006-04-28 ES ES17156762T patent/ES2906792T3/es active Active
- 2006-04-28 EP EP12159079.8A patent/EP2527007B1/fr active Active
- 2006-04-28 SI SI200632410T patent/SI3372281T1/sl unknown
- 2006-04-28 SI SI200631703T patent/SI1874117T1/sl unknown
- 2006-04-28 PT PT161545314T patent/PT3045206T/pt unknown
- 2006-04-28 PL PL16154531T patent/PL3045206T3/pl unknown
- 2006-04-28 DK DK12159082.2T patent/DK2465580T3/en active
- 2006-04-28 DK DK06758843.4T patent/DK1874117T3/da active
- 2006-04-28 ES ES06758843.4T patent/ES2437268T3/es active Active
- 2006-04-28 PT PT181666215T patent/PT3372281T/pt unknown
- 2006-04-28 PL PL12159082T patent/PL2465580T3/pl unknown
- 2006-04-28 EA EA200702080A patent/EA014162B1/ru active Protection Beyond IP Right Term
- 2006-04-28 PL PL17195280T patent/PL3284520T3/pl unknown
- 2006-04-28 LT LTEP18166621.5T patent/LT3372281T/lt unknown
- 2006-04-28 PL PL06758843T patent/PL1874117T3/pl unknown
- 2006-04-28 CA CA2606282A patent/CA2606282C/fr active Active
- 2006-04-28 EP EP16154531.4A patent/EP3045206B2/fr active Active
- 2006-04-28 US US11/919,386 patent/US8129385B2/en active Active
- 2006-04-28 PT PT121590822T patent/PT2465580E/pt unknown
- 2006-04-28 LT LTEP17195280.7T patent/LT3284520T/lt unknown
- 2006-04-28 ES ES18166621T patent/ES2892304T3/es active Active
- 2006-04-28 BR BRPI0610030A patent/BRPI0610030B8/pt active IP Right Grant
- 2006-04-28 ES ES12159079.8T patent/ES2567197T3/es active Active
- 2006-04-28 TW TW095115285A patent/TWI378931B/zh active
- 2006-04-28 HU HUE16154531A patent/HUE037795T2/hu unknown
- 2006-04-28 SI SI200632418T patent/SI3187225T1/sl unknown
- 2006-04-28 ES ES17195280T patent/ES2743531T3/es active Active
- 2006-04-28 HU HUE18166621A patent/HUE056603T2/hu unknown
- 2006-04-28 WO PCT/US2006/016604 patent/WO2006116764A1/fr active Application Filing
- 2006-04-28 EP EP17195280.7A patent/EP3284520B1/fr active Active
- 2006-04-28 AU AU2006239177A patent/AU2006239177B8/en active Active
- 2006-04-28 EP EP17156762.1A patent/EP3187225B1/fr not_active Not-in-force
- 2006-04-28 JP JP2008509227A patent/JP4295353B2/ja active Active
- 2006-04-28 DK DK17195280.7T patent/DK3284520T3/da active
- 2006-04-28 DK DK17156762.1T patent/DK3187225T3/da active
- 2006-04-28 PT PT67588434T patent/PT1874117E/pt unknown
- 2006-04-28 DK DK16154531.4T patent/DK3045206T3/en active
2007
- 2007-10-10 NO NO20075165A patent/NO339525B1/no active Protection Beyond IP Right Term
- 2007-10-10 IL IL186555A patent/IL186555A/en active IP Right Grant
- 2007-10-25 MX MX2011010484A patent/MX312216B/es unknown
- 2007-11-20 MA MA30388A patent/MA29460B1/fr unknown
2008
- 2008-01-24 HK HK08100942.1A patent/HK1107227A1/xx unknown
- 2008-10-08 JP JP2008261344A patent/JP2009079058A/ja active Pending
2011
- 2011-10-23 IL IL215788A patent/IL215788A0/en unknown
2012
- 2012-01-18 US US13/352,686 patent/US8410103B2/en active Active
- 2012-12-18 HK HK12113039.2A patent/HK1172282A1/xx unknown
2013
- 2013-02-08 US US13/763,174 patent/US8778943B2/en active Active
- 2013-03-14 IL IL225206A patent/IL225206A/en active IP Right Grant
- 2013-03-14 IL IL225207A patent/IL225207A/en active IP Right Review Request
- 2013-11-27 CY CY20131101061T patent/CY1115151T1/el unknown
2014
- 2014-03-13 CY CY20141100201T patent/CY1116331T1/el unknown
- 2014-03-14 US US14/211,364 patent/US9051337B2/en active Active
- 2014-05-07 LU LU92446C patent/LU92446I2/fr unknown
- 2014-05-19 FR FR14C0041C patent/FR14C0041I2/fr active Active
- 2014-06-25 CY CY2014024C patent/CY2014024I2/el unknown
- 2014-07-03 NL NL300676C patent/NL300676I2/nl unknown
- 2014-07-09 HU HUS1400039C patent/HUS1400039I1/hu unknown
2015
- 2015-04-30 US US14/700,679 patent/US9273065B2/en active Active
2016
- 2016-01-20 US US15/001,336 patent/US20160137666A1/en not_active Abandoned
- 2016-03-31 US US15/086,616 patent/US20160207939A1/en not_active Abandoned
- 2016-06-29 US US15/196,245 patent/US20160304535A1/en not_active Abandoned
- 2016-08-18 NO NO20161315A patent/NO340111B1/no active Protection Beyond IP Right Term
- 2016-10-11 US US15/290,094 patent/US20170029438A1/en not_active Abandoned
2017
- 2017-02-08 US US15/427,184 patent/US20170145033A1/en not_active Abandoned
- 2017-03-27 NO NO2017010C patent/NO2017010I2/no unknown
- 2017-04-10 US US15/482,896 patent/US20170209454A1/en not_active Abandoned
- 2017-04-27 US US15/498,667 patent/US20170224694A1/en not_active Abandoned
- 2017-04-27 US US15/498,684 patent/US20170224695A1/en not_active Abandoned
- 2017-05-17 US US15/597,343 patent/US20170253616A1/en not_active Abandoned
- 2017-05-18 US US15/598,655 patent/US20170260203A1/en not_active Abandoned
- 2017-05-18 US US15/598,671 patent/US20170267693A1/en not_active Abandoned
- 2017-09-07 US US15/697,847 patent/US20170369509A1/en not_active Abandoned
2018
- 2018-06-19 CY CY20181100633T patent/CY1120345T1/el unknown
- 2018-07-16 HK HK18109159.8A patent/HK1249742A1/zh unknown
- 2018-08-16 HK HK18110519.1A patent/HK1251191A1/zh unknown
2019
- 2019-01-10 US US16/244,441 patent/US20190152990A1/en not_active Abandoned
- 2019-05-01 US US16/400,373 patent/US10927129B2/en active Active
- 2019-08-20 CY CY20191100891T patent/CY1122052T1/el unknown
2020
- 2020-07-09 US US16/924,390 patent/US11267823B2/en active Active
2021
- 2021-05-10 NO NO2021018C patent/NO2021018I1/no unknown
- 2021-05-26 CY CY2021016C patent/CY2021016I2/el unknown
- 2021-06-08 NL NL301109C patent/NL301109I2/nl unknown
- 2021-06-10 FI FIC20210017C patent/FIC20210017I1/fi unknown
- 2021-06-14 HU HUS2100022C patent/HUS2100022I1/hu unknown
- 2021-06-14 HU HUS2100023C patent/HUS2100023I1/hu unknown
- 2021-06-15 LU LU00210C patent/LUC00210I2/en unknown
- 2021-06-16 LT LTPA2021512C patent/LTC2465580I2/lt unknown
- 2021-10-06 CY CY20211100866T patent/CY1124601T1/el unknown
2022
- 2022-01-27 US US17/586,006 patent/US20220213121A1/en not_active Abandoned
2023
- 2023-11-08 NO NO2023042C patent/NO2023042I1/no unknown
2024
- 2024-04-09 US US18/630,561 patent/US20240279238A1/en active Pending

Also Published As

Publication number	Publication date
US8410103B2 (en)	2013-04-02
KR20160003889A (ko)	2016-01-11
US9273065B2 (en)	2016-03-01
PT3284520T (pt)	2019-09-10
PL3372281T3 (pl)	2021-12-27
EP2527007B1 (fr)	2016-03-30
SI1874117T1 (sl)	2014-01-31
EA014162B1 (ru)	2010-10-29
ES2743531T3 (es)	2020-02-19
CY2021016I2 (el)	2021-12-31
KR20140097438A (ko)	2014-08-06
US20190284208A1 (en)	2019-09-19
US20130172559A1 (en)	2013-07-04
LTC2465580I2 (fr)	2022-10-10
US20170267693A1 (en)	2017-09-21
IL225207A (en)	2017-11-30
EP1874117A4 (fr)	2009-12-30
HK1172282A1 (en)	2013-04-19
HUS1400039I1 (hu)	2016-08-29
CY1120345T1 (el)	2019-07-10
JP2009079058A (ja)	2009-04-16
EP3045206A1 (fr)	2016-07-20
CY2014024I1 (el)	2015-12-09
DK3372281T3 (da)	2021-09-27
NL301109I1 (nl)	2021-09-15
NO20161315A1 (no)	2007-11-22
PL2465580T3 (pl)	2014-05-30
ES2446324T3 (es)	2014-03-07
ES2437268T3 (es)	2014-01-09
ES2667868T5 (es)	2023-06-01
US20160304535A1 (en)	2016-10-20
EA200702080A1 (ru)	2008-04-28
US11267823B2 (en)	2022-03-08
EP3187226A1 (fr)	2017-07-05
NO2021018I1 (no)	2021-05-10
EP2465580A1 (fr)	2012-06-20
PT1874117E (pt)	2013-10-17
US20170260203A1 (en)	2017-09-14
EP3284520B1 (fr)	2019-06-05
IL186555A0 (en)	2008-01-20
CY1116331T1 (el)	2017-02-08
EP2527007A1 (fr)	2012-11-28
NL301109I2 (nl)	2021-09-15
PT2465580E (pt)	2014-02-25
KR20080009733A (ko)	2008-01-29
AU2006239177B8 (en)	2012-02-16
CY1115151T1 (el)	2015-12-09
EP1874117A1 (fr)	2008-01-09
CY1122052T1 (el)	2020-10-14
BRPI0610030B1 (pt)	2020-09-15
NO339525B1 (no)	2016-12-27
KR101504998B1 (ko)	2015-03-23
ES2567197T3 (es)	2016-04-20
US8778943B2 (en)	2014-07-15
JP2008540343A (ja)	2008-11-20
US20190152990A1 (en)	2019-05-23
DK3187225T3 (da)	2022-02-28
EP3045206B2 (fr)	2023-02-15
DK2465580T3 (en)	2014-03-10
LT3372281T (lt)	2021-12-10
HK1249742A1 (zh)	2018-11-09
CY2014024I2 (el)	2015-12-09
US20200339598A1 (en)	2020-10-29
SI2465580T1 (sl)	2014-04-30
SI3187225T1 (sl)	2022-04-29
US20170145033A1 (en)	2017-05-25
FR14C0041I1 (fr)	2014-06-27
VN34404A1 (en)	2013-07-25
US20150232479A1 (en)	2015-08-20
IL215788A0 (en)	2011-12-29
NO2017010I1 (no)	2017-03-27
NO340111B1 (no)	2017-03-13
EP3187225B1 (fr)	2022-01-05
IL186555A (en)	2016-10-31
HUE037795T2 (hu)	2018-09-28
US20160207939A1 (en)	2016-07-21
LU92446I2 (fr)	2015-10-29
NZ562339A (en)	2011-01-28
EP3284519A8 (fr)	2018-04-18
EP3284520A1 (fr)	2018-02-21
EP1874117B1 (fr)	2013-08-28
DK1874117T3 (da)	2013-09-23
DK3284520T3 (da)	2019-09-16
ES2892304T3 (es)	2022-02-03
US20240279238A1 (en)	2024-08-22
EP3284519A1 (fr)	2018-02-21
US8129385B2 (en)	2012-03-06
CY2021016I1 (el)	2021-10-15
NO2017010I2 (no)	2017-03-27
TW200716635A (en)	2007-05-01
KR20130133061A (ko)	2013-12-05
US20140200209A1 (en)	2014-07-17
NL300676I2 (fr)	2016-10-11
DK3045206T3 (en)	2018-05-22
HK1107227A1 (en)	2008-04-03
US20120115875A1 (en)	2012-05-10
US20090318421A1 (en)	2009-12-24
AU2006239177A1 (en)	2006-11-02
EP3187225A1 (fr)	2017-07-05
LTPA2021512I1 (fr)	2021-07-12
AU2006239177B2 (en)	2011-10-20
EP1874117B8 (fr)	2014-03-12
US20170224694A1 (en)	2017-08-10
PL1874117T3 (pl)	2014-01-31
NO2023042I1 (no)	2023-11-08
PL3284520T3 (pl)	2020-01-31
SI3045206T1 (en)	2018-07-31
KR101848819B1 (ko)	2018-04-16
EP3045206B1 (fr)	2018-03-28
US20170209454A1 (en)	2017-07-27
MX2007013351A (es)	2008-01-21
CY1124601T1 (el)	2022-07-22
LT3284520T (lt)	2019-09-25
PT3372281T (pt)	2021-10-14
BRPI0610030A2 (pt)	2011-10-11
LT3045206T (lt)	2018-06-11
HUE056603T2 (hu)	2022-02-28
KR101580310B1 (ko)	2016-01-04
EP3372281A1 (fr)	2018-09-12
CA2606282A1 (fr)	2006-11-02
SI3284520T1 (sl)	2019-10-30
PL3045206T3 (pl)	2018-08-31
TWI378931B (en)	2012-12-11
US20170253616A1 (en)	2017-09-07
MX302718B (es)	2012-08-27
BRPI0610030B8 (pt)	2022-01-11
FIC20210017I1 (fi)	2021-06-10
ES2906792T3 (es)	2022-04-20
NO20075165L (no)	2007-11-22
JP4295353B2 (ja)	2009-07-15
PT3045206T (pt)	2018-07-05
HUS2100022I1 (hu)	2021-07-28
US20220213121A1 (en)	2022-07-07
CA2606282C (fr)	2016-04-26
HUS2100023I1 (hu)	2021-07-28
MX312216B (en)	2013-08-12
HK1251191A1 (zh)	2019-01-25
WO2006116764A1 (fr)	2006-11-02
ES2667868T3 (es)	2018-05-14
US20170224695A1 (en)	2017-08-10
EP2465580B1 (fr)	2013-12-18
IL225206A (en)	2017-11-30
US9051337B2 (en)	2015-06-09
HUE044978T2 (hu)	2019-11-28
MA29460B1 (fr)	2008-05-02
US10927129B2 (en)	2021-02-23
US20170369509A1 (en)	2017-12-28
EP3372281B1 (fr)	2021-07-07
KR101363875B1 (ko)	2014-02-21
US20160137666A1 (en)	2016-05-19
US20170029438A1 (en)	2017-02-02
SI3372281T1 (sl)	2021-11-30
LUC00210I2 (fr)	2022-10-07

Publication	Publication Date	Title
FR14C0041I2 (fr)	2015-11-13	Derive polycyclique de la carbamoylpyridone a activite inhibitrice sur l'integrase du vih
IL190879A0 (en)	2008-11-03	Polycyclic carbamoylpyridone derivative having inhibitory activity on hiv integrase
MA28358A1 (fr)	2006-12-01	Inhibiteurs de l'integrase du vih
MA28519B1 (fr)	2007-04-03	Inhibiteurs de l'integrase du vih
EP1790638A4 (fr)	2009-10-28	Dérivé de carbamoylpyridone ayant une activité d'inhibition de la vih intégrase
JP2008523076A5 (fr)	2009-02-05
ZA200803423B (en)	2009-08-26	Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
FI20050577A0 (fi)	2005-05-31	Menetelmä adamantaanijohdannaisten valmistamiseksi
FR2888487B1 (fr)	2009-11-20	Casque de mesure de l'activite cerebrale
ITBO20050490A1 (it)	2007-01-23	Apparecchiatura perfezionata per l'applicazione di decori a secco su corrispondenti articoli
ITVB20050003U1 (it)	2005-12-02	Trasduttore "penn"
ITGE20040052A1 (it)	2004-09-14	Apparecchiatura biomedicale denominata "oscillometria posturale"